Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis

重性抑郁障碍 精神科 耐受性 医学 抑郁症状 荟萃分析 心理学 内科学 不利影响 儿科 心情 认知
作者
Andrea Cipriani,Xinyu Zhou,Cinzia Del Giovane,Sarah Elisabeth Hetrick,Bin Qin,Craig J. Whittington,David Coghill,Yuqing Zhang,Philip Hazell,Stefan Leucht,Pim J. Cuijpers,Juncai Pu,David Cohen,Arun V Ravindran,Yiyun Liu,Kurt D. Michael,Lining Yang,Lanxiang Liu,Peng Xie
出处
期刊:The Lancet [Elsevier BV]
卷期号:388 (10047): 881-890 被引量:847
标识
DOI:10.1016/s0140-6736(16)30385-3
摘要

Summary

Background

Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.

Methods

We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.

Findings

We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference −0·51, 95% credible interval [CrI] −0·99 to −0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I2 values were 33·21% for efficacy and 0% for tolerability.

Interpretation

When considering the risk–benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.

Funding

National Basic Research Program of China (973 Program).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage的应助被诗酒采纳,获得10
刚刚
刚刚
Kelly发布了新的文献求助10
1秒前
斯多姆发布了新的文献求助30
1秒前
宠仙完成签到,获得积分10
1秒前
跳跃的谷秋完成签到,获得积分10
1秒前
Rryang完成签到,获得积分10
1秒前
1秒前
胡图图发布了新的文献求助10
2秒前
chaojia_niu发布了新的文献求助10
2秒前
xxxx完成签到 ,获得积分10
3秒前
罗氏集团发布了新的文献求助10
3秒前
大个的应助被蓝桉采纳,获得10
3秒前
3秒前
wuwa完成签到,获得积分10
4秒前
4秒前
lzs发布了新的文献求助10
4秒前
科目三的应助被跳跃的谷秋采纳,获得10
4秒前
4秒前
jiehe发布了新的文献求助10
5秒前
5秒前
TU完成签到,获得积分10
5秒前
NexusExplorer的应助被焓舒采纳,获得10
5秒前
热心的冬菱完成签到 ,获得积分10
6秒前
6秒前
7秒前
8秒前
111发布了新的文献求助20
8秒前
hyunjj_niel发布了新的文献求助20
8秒前
李健的小迷弟的应助被荷序采纳,获得10
9秒前
占曼荷发布了新的文献求助10
10秒前
落后凝莲发布了新的文献求助10
10秒前
11秒前
11秒前
罗舒发布了新的文献求助10
11秒前
一心完成签到,获得积分10
11秒前
英勇白莲完成签到,获得积分10
11秒前
123完成签到,获得积分10
12秒前
qkd1119发布了新的文献求助10
13秒前
北斗文曲星完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192078
求助须知:如何正确求助?哪些是违规求助? 9578698
关于积分的说明 21861559
捐赠科研通 7791583
什么是DOI,文献DOI怎么找? 3436814
关于科研通互助平台的介绍 2560538
邀请新用户注册赠送积分活动 2483582